Caution is advised in the treatment of patients with a history of peptic ulcer. Clinical intolerance to Serc in bronchial asthma patients has been shown in a relatively few patients. These patients need to be carefully monitored during the therapy.

Serc 8mg Tablets * Pharmacy Only: Prescription . Company: Mylan IRE Healthcare Ltd ; Status: No Recent Update ; ... Betahistine Dihydrochloride *Additional information is available within the SPC or upon request to the company . Scan the QR code or enter an email to access and share this medicine: Submit . SPC ; Patient Leaflets ; Licence Info ...

instructions regarding how and when to take Serc. What is Serc† and what is it used for? Serc† is the brand name for a drug called “betahistine dihydrochloride”. Serc is used for reducing the episodes of recurrent vertigo associated with Meniere’s disease.

Serc is available in two strengths, an 8 mg tablet and a 16 mg tablet. The usual starting dose is 16 mg three times a day (48 mg). Your doctor may lower your dose to 8 mg three times a day (24 mg). Keep taking your tablets. The tablets can take a while to start to work. Serc is not recommended for those under 18 years old.

2014年6月13日 · Page 1 of 2 PACKAGE LEAFLET: INFORMATION FOR THE USER SERC 16MG TABLETS (betahistine dihydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you.

Each tablet contains 8 mg betahistine dihydrochloride equivalent to 5.21mg betahistine. There are no adequate data from the use of betahistine in pregnant women. Animal studies are insufficient with respect to effects on pregnancy, embryonal/foetal development, parturition and postnatal development. The potential risk for humans is unknown.

Serc® (Betaserc®, Vasomotal®, betahistine dihydrochloride) of Solvay Pharmaceuticals is the world market leader in the treatment of Ménière’s disease and vestibular vertigo. Serc® was first registered in Europe in 1970 for the treatment of Ménière’s disease.

Betahistine dihydrochloride is a histamine-like drug in which pharmacological activity can be attributed to a specific effects and/or more direct influences on recovery mechanisms the vestibular nuclei. It has weak agonist activity at histamine H 1 receptors and moderate antagonist activity at H 3 receptors.

Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals.

Betahistine is used to reduce the number of episodes of vertigo associated with Ménière's disease. It is believed to work by decreasing the pressure in the ear. This pressure is believed to contribute to the sense of dizziness, nausea, and ringing in the ears and hearing loss that people with Ménière's disease experience.